Connect Biopharma (NASDAQ: CNTB) releases Q2 and first-half 2025 results

Rhea-AI Filing Summary

Connect Biopharma Holdings Limited filed a current report to note that it has released its latest financial results. On August 13, 2025, the company issued a press release covering its results for the three and six months ended June 30, 2025, and attached that release as an exhibit to this report.

The filing itself mainly serves as a formal notice that the earnings press release is available and clarifies that this information is being "furnished" rather than "filed" under securities laws. The report is signed by Lisa Peraza, Senior Vice President, Finance, on behalf of the company.

0001835268false00018352682025-08-132025-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________________

FORM 8-K

________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

________________________________________

Connect Biopharma Holdings Limited

(Exact name of Registrant as Specified in Its Charter)

________________________________________

Cayman Islands			001-40212			Not Applicable
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
			3580 Carmel Mountain Road, Suite 200
			San Diego, California			92130
			(Address of Principal Executive Offices)			(Zip Code)

Registrant’s Telephone Number, Including Area Code: (877) 245-2787

________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

American Depositary Shares, each representing one Ordinary Share, par value $0.000174 per Share

CNTB

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Connect Biopharma Holdings Limited (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release of the Company, dated August 13, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									CONNECT BIOPHARMA HOLDINGS LIMITED
Date:			August 13, 2025			By:			/s/ Lisa Peraza
						Name:			Lisa Peraza
						Title:			Senior Vice President, Finance

FAQ

What did Connect Biopharma (CNTB) disclose in this 8-K?

Connect Biopharma disclosed that it issued a press release announcing financial results for the three and six months ended June 30, 2025, which is attached as Exhibit 99.1.

Which period do Connect Biopharma’s latest results cover?

The press release attached to the report covers the company’s financial results for the three and six months ended June 30, 2025.

Where can investors find the detailed Q2 2025 results for CNTB?

The detailed results are contained in the company’s press release dated August 13, 2025, which is attached as Exhibit 99.1 to this report.

Is the financial information in this CNTB report considered “filed” with the SEC?

No. The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished and is not deemed "filed" for purposes of Section 18 of the Exchange Act.

Who signed this Connect Biopharma (CNTB) 8-K?

The report was signed on behalf of Connect Biopharma by Lisa Peraza, who is the company’s Senior Vice President, Finance.

What exhibits are included with this Connect Biopharma 8-K?

The report includes Exhibit 99.1, the press release dated August 13, 2025, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.